Clinical trials
Human Papillomavirus clinical trials
Below are recruiting human papillomavirus clinical trials, each written for real people, not researchers. We’re tracking 65 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05266898RecruitingPhase 4
HPV vaccine response study for people living with HIV
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
New Orleans, LouisianaAges 18–65 - NCT07706673Enrolling by invitationPhase 4
Long-term follow-up for HPV vaccine study participants
This study checks on people who got one or two doses of the HPV vaccine (Gardasil 9) during the earlier ESCUDDO study. It helps researchers see how well the vaccine protects over many years, which might lead to simpler vaccination schedules.
Liberia, Guanacaste ProvinceAges 18 years+ - NCT06434337Recruiting
HPV diagnostic test study
This study tests a new, quick diagnostic test for HPV (the virus that can cause cervical cancer). Researchers want to see if the test works well compared to regular tests. If you are due for an HPV test or a related procedure, this study may be a good fit.
Houston, TexasAges 21 years+ - NCT07601074RecruitingPhase 2
Testing DARE-HPV to Clear Persistent HPV Infection
This study tests whether DARE-HPV, a new treatment, can help your body clear a persistent human papillomavirus (HPV) infection that hasn't gone away on its own. HPV is a common virus; persistent infection with certain high-risk types can lead to cervical cancer, so clearing it early may prevent future problems.
Phoenix, ArizonaAges 22–50 - NCT07186530Enrolling by invitation
HPV self-collection for cervical cancer screening
This trial tests a new way for women to screen for cervical cancer by collecting their own sample for HPV testing at home or in a clinic. It aims to make screening easier for those who are overdue and may be anxious about a pelvic exam.
Rochester, MinnesotaAges 30–63 - NCT06544720RecruitingPhase 1
SCG142 TCR-T cell therapy for HPV-related cancers
This trial tests a new treatment called SCG142 TCR-T cells for cancers caused by HPV. The therapy uses your own immune cells to fight the tumor. It may help if other treatments haven't worked or are not available.
Qingdao, ShandongAges 18 years+ - NCT07833852Enrolling by invitation
Long-term protection study for bivalent HPV vaccine
This study follows up with people who received the bivalent HPV vaccine to see how long their protection lasts and whether any breakthrough infections occur. It involves extra blood tests or follow-up visits over several years.
Mianyang, SichuanAges 12–34 - NCT05625633RecruitingPhase 2/Phase 3
HPV vaccine vs placebo for stubborn skin warts
This study tests whether an HPV vaccine can help shrink or clear cutaneous (skin) warts that have not responded to prior treatments. Participants get the study vaccine or a placebo to compare results and safety.
Salt Lake City, UtahAges 18 years+ - NCT06793410RecruitingPhase 2
HPV vaccine after stem cell transplant
This trial tests if the HPV vaccine works safely in people who received a stem cell transplant from a donor. It may help prevent HPV-related cancers in transplant survivors.
Lund, Region SkåneAges 18–45 - NCT07281430Recruiting
HPV self-test for cervical cancer screening
This study tests if a self-collected sample for HPV testing works as well as standard colposcopy to prevent cervical cancer. If you've recently had an abnormal cervical cancer screening and need a colposcopy, this trial may be an option for you.
Birmingham, AlabamaAges 25 years+ - NCT07275333Recruiting
HPV self-sampling for cervical screening in Ukraine
This trial tests if women can collect their own samples at home to check for HPV, a virus that can cause cervical cancer. It aims to make screening easier during the war in Ukraine.
ZaporizhzhyaAges 30–60 - NCT05334706RecruitingPhase 4
Vaccine study to lower HPV spread in HPV-positive women
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
L'Hospitalet de Llobregat, CataloniaAges 18 years+ - NCT05985681RecruitingPhase 1
Vaccine to prevent HPV-related cancers
This trial tests a new vaccine called RG1-VLP that may help prevent cancers caused by HPV. It is for healthy women who have not had an HPV vaccine before and are willing to follow study procedures.
Madison, WisconsinAges 18–60 - NCT06997094RecruitingPhase 1
Decitabine plus standard therapy for HPV-negative head and neck cancer
This trial tests whether adding the drug decitabine to standard treatment (surgery and possibly radiation) can help people with a type of head and neck cancer not caused by HPV. You would receive decitabine before surgery, and then continue with standard care after.
Jacksonville, FloridaAges 18 years+ - NCT07209917Recruiting
Cervical cancer prevention for women with HIV and HPV
This trial tests a new way to prevent cervical cancer in women with both HIV and HPV. It focuses on women in India who are already on stable HIV treatment and have a normal cervical exam.
Bangalore, KarnatakaAges 25–50 - NCT07248904Recruiting
HPV education study for first-year nursing students
This study tests whether a special education program based on the transtheoretical model improves nursing students' knowledge about HPV, their health beliefs, and their intentions to get vaccinated. It aims to help students make informed decisions about HPV prevention.
Adana, CUKUROVAAges 18 years+ - NCT06624839RecruitingPhase 2
HPV vaccine study for people with and without HIV
This study tests how well the Gardasil 9 HPV vaccine works in people assigned male at birth, including those with HIV and those taking hormone therapy. Results could help protect against HPV-related cancers.
Washington D.C., District of ColumbiaAges 18–70 - NCT07668271RecruitingPhase 4
HPV 9-valent vaccine lot consistency trial for women
This trial tests whether different batches of the HPV 9-valent vaccine work consistently. It's for Chinese women aged 18 to 30 who have not had any HPV vaccine or abnormal cervical screening results.
Zhangping, FujianAges 18–30 - NCT05262010RecruitingPhase 3
HPV vaccine study for Chinese women, ages 9–45
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
Hechi, GuangxiAges 18–45 - NCT07214584Recruiting
Using blood and cervical tests to track cervical cancer treatment response
This trial checks how well cervical cancer responds to surgery, radiation, and chemotherapy by measuring HPV DNA and RNA in blood and cervical mucus. It aims to improve monitoring during treatment.
Gainesville, FloridaAges 18–89 - NCT05026138Recruiting
Study of severe HPV disease and why it keeps coming back
This study follows people with severe or hard-to-treat HPV-related conditions (and some closely related partners/household contacts) to learn how the virus causes illness and how the immune system responds. It may help doctors better predict who will develop severe disease and guide future treatments.
Bethesda, MarylandAges 3–100 - NCT04422366RecruitingPhase 3
9-valent HPV vaccine study for healthy Chinese women
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
Liuzhou, GuangxiAges 20–45 - NCT04226313Recruiting
Home self-swab tests for people not doing cervical screening
This study looks at whether a home self-sampling swab can help people who haven’t joined cervical cancer screening in the past few years. If you qualify, you’ll be asked to collect a swab yourself so it can be tested, aiming to make screening easier to access.
OlomoucAges 30–65 - NCT04131413RecruitingPhase 1
HPV vaccine given through the skin for HPV16 cervical disease
This early-phase study tests a vaccine designed to help your immune system fight HPV16, a type of human papillomavirus linked to abnormal cells in the cervix. You may or may not be living with HIV, and the team will check safety and immune response after giving the vaccine in a specific way.
Birmingham, AlabamaAges 19 years+
Hear when a new Human Papillomavirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for human papillomavirus?
- Yes. Clin2 currently lists 65 recruiting human papillomavirus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a human papillomavirus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a human papillomavirus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.